<DOC>
	<DOC>NCT01683396</DOC>
	<brief_summary>The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of active inflammatory, erosive osteoarthritis of the hand.</brief_summary>
	<brief_title>Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosis of hand osteoarthritis Joint tenderness and/or redness At least one erosion by Xray (as determined by the central reader) Contraceptive measures adequate to prevent pregnancy during the study History of inflammatory disease other than hand EOA including: secondary posttraumatic OA; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia History of gout, pseudogout, or hemochromatosis History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent or chronic systemic infections Known allergy to acetaminophen Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Erosive Osteoarthritis</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Osteoarthritis of the Hand</keyword>
</DOC>